Key result
Monitoring low molecular weight heparin therapy with the thrombodynamics test detected significant coagulation changes (p<0.05) in pregnant women with first-trimester pathology.
Why the study?
Does the thrombodynamics test effectively monitor low molecular weight heparin therapy in pregnant women with first-trimester pregnancy pathology?
Population
23 pregnant women with pregnancy pathology and/or history of thrombosis and threatening miscarriage in the…
Design
Cohort
Follow-up
up to 38-40 weeks gestation
Authors
Loading...
Thrombodynamics may aid LMWH monitoring in high-risk pregnancies; leaves open need for randomized confirmation before practice change.
Observational (n=23)
Does the thrombodynamics test effectively monitor low molecular weight heparin therapy in pregnant women with first-trimester pregnancy pathology?
p-value: p=<0.05
The thrombodynamics test provides a sensitive method for monitoring low molecular weight heparin therapy in pregnant women with thrombophilia or threatening miscarriage.
Galaiko et al. (2017) conducted an observational in Pregnancy pathology and/or history of thrombosis and threatening miscarriage (n=23). Thrombodynamics test monitoring of low molecular weight heparin (LMWH) was evaluated on Changes in thrombodynamics indices (p=<0.05). Monitoring low molecular weight heparin therapy with the thrombodynamics test detected significant coagulation changes (p<0.05) in pregnant women with first-trimester pathology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: